<TITLE> KXNAME AKORN INC</TITLE> 
<DOCUMENT>
<TYPE>EX-10.72
<SEQUENCE>2
<FILENAME>c50093exv10w72.htm
<DESCRIPTION>EX-10.72
<TEXT>
<HTML>
<HEAD>
<TITLE>exv10w72</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;10.72</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Confidential Treatment Requested Under<BR>
17 C.F.R. &#167;&#167; 200.80(b)(4) and 240.24b-2</B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="10%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="60%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><IMG src="c50093c5009302.gif" alt="(UMASS LOGO)">
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>MassBiologics</B><br>
University of Massachusetts Medical School<br>
460 Walk Hill Street, Boston, MA 02126</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Telephone: 617-474-3000 Facsimile: 617-474-3240</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">March&nbsp;27, 2009
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><U>Via Email And FedEx</U>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">John N. Kapoor, Ph.D., Chairman<BR>
Akorn, Inc.<BR>
1925 West Field Court, Suite&nbsp;300<BR>
Lake Forest, IL 60045<BR>
jkapoor@ejfinancial.com

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Re: Distribution Agreement &#150; Revised Proposal
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Dear John:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I write with respect to resolving various issues arising under the Exclusive Distribution
Agreement, dated as of March&nbsp;22, 2007, between Akorn, Inc. (&#147;<B>Akorn</B>&#148;) and the Massachusetts Biologic
Laboratories of the University of Massachusetts (&#147;<B>MBL</B>&#148;) (as amended, our &#147;<B>Distribution Agreement</B>&#148;).
MBL makes Akorn the following offer to resolve the parties&#146; outstanding issues, and to amend the
Distribution Agreement accordingly (the &#147;<B>Offer</B>&#148;):
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.&nbsp;Amount Owed</B>.&nbsp; Giving effect to Akorn&#146;s payment of $1,000,000 on March&nbsp;13, 2009 (the &#147;<B>$1
Million Payment"</B>), Akorn currently owes MBL $5,750,000&nbsp;million for Td vaccine shipments delivered
and accepted (the &#147;<B>Amount Owed</B>&#148;). Payment of the Amount Owed is past due.&nbsp;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>2.&nbsp;Failure to Pick-Up</B>. Akorn acknowledges its failure to take delivery of the shipment of
<B>&#091;***...***&#093; </B>doses of Td vaccine scheduled for Akorn&#146;s pick-up on March&nbsp;11, 2009, as required under
the Distribution Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>3.&nbsp;Total Amount Owed</B>. In exchange for the Distribution Agreement amendments set out in
Section&nbsp;6 (Distribution Provisions), Akorn hereby agrees to pay to MBL the additional amount of
$4,750,000 (such amount together with the Amount Owed, the &#147;<B>Total Amount</B>&#148;). &nbsp;The Total Amount,
therefore, equals $10,500,000.00.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>4.&nbsp;Pay-Off</B>. Akorn shall pay the remaining Total Amount by wire transfer in accordance with
the payment schedule attached as Exhibit&nbsp;A (&#147;<B>Payment Schedule</B>&#148;). Wire transfer instructions are as
follows:&nbsp;
</DIV>
<DIV align="left" style="font-size: 10pt; margin-left: 9%; margin-top: 6pt">BANK OF AMERICA, N.A.
</DIV>



<DIV align="left">
<DIV style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96"></TD>
</TR>

<TR valign="top">
    <TD nowrap align="left">*</TD>
    <TD>&nbsp;</TD>
    <TD>CONFIDENTIAL TREATMENT REQUESTED &#151; This language has been omitted and filed separately with the Securities and Exchange Commission.</TD>
</TR>

</TABLE>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Confidential Treatment Requested Under<BR>
17 C.F.R. &#167;&#167; 200.80(b)(4) and 240.24b-2</B>

</DIV>
<DIV align="left" style="font-size: 10pt; margin-left: 9%; margin-top: 6pt">ABA Routing <B>&#091;***...***&#093;</B><BR>
Account <B>&#091;***...***&#093;</B><BR>
Checking Account<BR>
Bank Phone # (800)&nbsp;432-1000
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>5.&nbsp;Standby Irrevocable Letter of Credit</B>. As security for the timely payment by Akorn of the
Total Amount in accordance with the Payment Schedule, and to reimburse MBL in the event any such
payment (or any portion thereof) and/or the $1 Million Payment (or any portion thereof) is avoided,
set aside, or otherwise required to be repaid by MBL (whether pursuant to or in connection with a
bankruptcy or similar proceeding involving Akorn or otherwise), Akorn or its designee shall provide
to MBL on or before April&nbsp;13, 2009 (the &#147;<B>LOC Delivery Date</B>&#148;) an irrevocable transferable standby
letter of credit that meets the following three criteria: the letter of credit shall be (i)&nbsp;in form
and substance reasonably satisfactory to MBL (provided that MBL shall not make unreasonable
modifications to the bank&#146;s form letter of credit); (ii)&nbsp;in the amount of $10,500,000.00, and (iii)
confirmed by a United States bank acceptable to MBL (the &#147;<B>Letter of Credit</B>&#148;). Provided (x)&nbsp;on or
before April&nbsp;6, 2009, Akorn delivers to the issuing bank all documents and materials (other than
funding), needed by the bank to issue a Letter of Credit meeting the requirements of the previous
sentence, (y)&nbsp;Akorn does not request changes to this Letter of Credit after April&nbsp;6, 2009 (unless
the request is objectively based on clear and convincing justification), and (z)&nbsp;the Letter of
Credit is funded by Akorn as of April&nbsp;13, 2009, then the LOC Delivery Date shall be extended on a
day for day basis for each day of negotiations between MBL and the issuing bank over the form and
substance of the Letter of Credit which continue subsequent to April&nbsp;13, 2009. MBL will be able to
draw on such Letter of Credit but, in each case, only in the amount not so paid or so avoided, set
aside, or repaid, at such time (a)&nbsp;that any required payment in respect of the Total Amount is not
timely paid according to the Payment Schedule, or (b)&nbsp;that any such payment (or any portion
thereof) is avoided, is set aside, recovered or is otherwise required to be repaid by MBL, or (c)
that the $1 Million Payment (or any portion thereof) is avoided, set aside, recovered or is
otherwise required to be repaid by MBL. Provided that no bankruptcy, receivership or other similar
proceeding is filed by or against Akorn within the 95&nbsp;day period immediately subsequent to each
payment of the Total Amount in accordance with the Payment Schedule, then the amount of the Letter
of Credit shall be reduced by the amount of such payment, and such reduction shall take place 95
days after each associated payment. The Letter of Credit shall not expire until 95&nbsp;days after the
sooner to occur of payment in full in immediately available funds of the Total Amount or June&nbsp;30,
2010, provided, however in the event that prior to the expiration of such 95&nbsp;day period, a
bankruptcy, receivership or other similar proceeding is filed by or against Akorn, the Letter of
Credit shall not expire until all applicable time limitation periods (including under Section&nbsp;546
of the Bankruptcy Code) relating to the avoidance, setting aside, recovery or repayment of any
payments made by Akorn to MBL in respect of the Total Amount or the $1 Million Payment shall have
expired and no action, litigation or other proceeding in respect thereof shall have been commenced
against MBL or, if any such action, litigation or other proceeding shall have been so commenced,
the same shall have been resolved by a final order of a court of competent jurisdiction and 5&nbsp;days
from the entry of such order shall have passed.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>6.&nbsp;Distribution Provisions</B>
</DIV>


<DIV align="left">
<DIV style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96"></TD>
</TR>

<TR valign="top">
    <TD nowrap align="left">*</TD>
    <TD>&nbsp;</TD>
    <TD>CONFIDENTIAL TREATMENT REQUESTED &#151; This language has been omitted and filed separately with the Securities and Exchange Commission.</TD>
</TR>

</TABLE>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Confidential Treatment Requested Under<BR>
17 C.F.R. &#167;&#167; 200.80(b)(4) and 240.24b-2</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>6.1 Provisions Taking Immediate Effect</B>. The following amendments to the Distribution
Agreement shall become effective as of Akorn&#146;s acceptance of this Offer:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.1.1 <B>Non-Exclusive Distribution</B>. Akorn will no longer act as MBL&#146;s exclusive distributor
under the Distribution Agreement and the Distribution Agreement will be amended to become
non-exclusive. Specifically, Akorn will be one of MBL&#146;s, but not the sole, FDA authorized
distributors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.1.2 <B>Pricing; Reduced Pricing</B>. Pricing to Akorn for Td Vaccine shall be as set out in the
Distribution Agreement; provided, however, that if MBL offers more favorable per dose pricing to
MBL&#146;s other distributors (&#147;<B>Reduced Per Dose Pricing</B>&#148;), then (i)&nbsp;MBL shall notify Akorn, and (ii)
during the period of such Reduced Per Dose Pricing, MBL shall offer the same Reduced Per Dose
Pricing to Akorn on orders that Akorn places and takes delivery on, during such period. These
Reduced Per Dose Pricing provisions shall not apply to any Td Vaccine sold by MBL under contracts
arising from CDC Solicitation Number 2009-N-11074 Vaccine for Children, and MBL&#146;s pricing under
such contracts shall not be effected by MBL&#146;s relationship with Akorn. MBL and others will be
entitled to sell to others MBL&#146;s Td Vaccines product labeled with Akorn&#146;s NDC currently in MBL&#146;s
possession.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.1.3 <B>Suspension of Minimum Purchase Obligations</B>. Akorn&#146;s obligation to make any further
minimum purchases of Td vaccine products and to otherwise comply with the delivery schedule set out
in the Distribution Agreement is hereby suspended through the LOC Delivery Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>6.2 Provisions Taking Effect upon Delivery of LOC</B>. On the strict condition that, in
compliance with the terms of this Offer, MBL receives the Letter of Credit on or before the LOC
Delivery Date (the &#147;<B>Required Condition</B>&#148;), the following amendments to the Distribution Agreement
will go into effect as of the LOC Delivery Date:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.2.1 <B>Removal of Minimum Purchase Obligation</B>. Upon fulfillment of the Required Condition (and
under no other circumstances), the Distribution Agreement shall be amended such that Akorn will not
be obligated to make any minimum purchases of Td vaccine products and will purchase on an as needed
basis with the quantity to be mutually agreed.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.2.2 <B>Resale on Termination; Termination without Cause</B>. Upon fulfillment of the Required
Condition (and under no other circumstances), the Distribution Agreement will also be amended to
include a revised termination provision eliminating the prohibition on the resale of product in the
event of a termination for cause and giving either party the right to terminate the agreement for
any reason without penalty on 90&nbsp;days written notice; provided, however, that such right to
terminate without cause shall not affect Akorn&#146;s obligations under sections 1, 3, and 4, above, or
MBL&#146;s rights hereunder (including under Section&nbsp;5, above) or under the Letter of Credit or the
Documents. Until termination thereof, Akorn would remain subject to all other provisions of the
Distribution Agreement (except as such provisions are expressly amended in accordance with this
proposal).
</DIV>


<DIV align="left">
<DIV style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96"></TD>
</TR>

<TR valign="top">
    <TD nowrap align="left">*</TD>
    <TD>&nbsp;</TD>
    <TD>CONFIDENTIAL TREATMENT REQUESTED &#151; This language has been omitted and filed separately with the Securities and Exchange Commission.</TD>
</TR>

</TABLE>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Confidential Treatment Requested Under<BR>
17 C.F.R. &#167;&#167; 200.80(b)(4) and 240.24b-2</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>7.&nbsp;Payment Terms</B>. For all future orders under the Distribution Agreement, payment terms will
be that Akorn shall pay for the order in full in cash upon placing the order with MBL.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>8.&nbsp;Amended Cure Period</B>. Akorn agrees that the cure period set out in Section 11(a) of the
Distribution Agreement is hereby amended such that, notwithstanding anything to the contrary
contained in the Distribution Agreement, (a)&nbsp;Akorn&#146;s ability and right to cure defaults or other
breaches of the Distribution Agreement in existence as of the date of this Offer shall expire as of
the LOC Delivery Date, and (b)&nbsp;the Distribution Agreement automatically shall terminate if, as of
the expiration of the LOC Delivery Date, Akorn has failed to fulfill the Required Condition.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>9.&nbsp;Information</B>.&nbsp; For the remaining duration of the Distribution Agreement, Akorn will deliver
to MBL by the fifth business day of each month (i)&nbsp;a monthly cash forecast for the MBL Td Vaccine
product to be sold pursuant to the Distribution Agreement (as amended by this letter agreement);
and (ii)&nbsp;monthly inventory and sales information for the MBL Td Vaccine product. Additionally
Akorn will deliver to MBL quarterly financial results as and when filed with the SEC.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>10.&nbsp;Documents</B>. Documents necessary to implement, or being delivered in connection with, this
Offer (including a forbearance agreement) (collectively, the &#147;<B>Documents</B>&#148;), shall conform in all
respects to the terms of this Offer, and shall otherwise be in form and substance mutually
reasonably acceptable to Akorn and MBL, provided. Akorn shall deliver draft Documents to MBL as
soon as practicable and the parties will work together in good faith to execute the Documents on or
before the LOC Delivery Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>11.&nbsp;Forbearance</B>. So long as Akorn complies with the terms hereof, the amended Distribution
Agreement, and the Documents, MBL will forebear from declaring a breach or otherwise acting to
terminate the Distribution Agreement, as amended hereby and in connection herewith.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>12.&nbsp;Binding Effect</B>. All terms material to the parties&#146; resolution of the current issues under
the Distribution Agreement are contained in this Offer and, once accepted by Akorn, these terms
shall be legally binding and fully enforceable.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If this Offer meets with your approval, please accept this Offer by signing below, and then
return to me one fully executed copy of this Offer no later than 10:00&nbsp;p.m., EDT March&nbsp;27, 2009,
after which date this Offer will expire.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="32%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Very truly yours,<BR></TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Massachusetts Biologic Laboratories of the University</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">of Massachusetts Medical School</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Donna M. Ambrosino, M.D.</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Donna M. Ambrosino, M.D.</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Director</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="left">
<DIV style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96"></TD>
</TR>

<TR valign="top">
    <TD nowrap align="left">*</TD>
    <TD>&nbsp;</TD>
    <TD>CONFIDENTIAL TREATMENT REQUESTED &#151; This language has been omitted and filed separately with the Securities and Exchange Commission.</TD>
</TR>

</TABLE>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Confidential Treatment Requested Under<BR>
17 C.F.R. &#167;&#167; 200.80(b)(4) and 240.24b-2</B>

</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><U><B>Agreed and Accepted by</B></U>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt">The undersigned hereby agrees to and accepts the Offer, as of March&nbsp;27, 2009.</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="32%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Akorn Inc.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ John N. Kapoor, P.h.D.</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">: John N. Kapoor, P.h.D.</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Chairman, Duly Authorized</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="left">
<DIV style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96"></TD>
</TR>

<TR valign="top">
    <TD nowrap align="left">*</TD>
    <TD>&nbsp;</TD>
    <TD>CONFIDENTIAL TREATMENT REQUESTED &#151; This language has been omitted and filed separately with the Securities and Exchange Commission.</TD>
</TR>

</TABLE>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Confidential Treatment Requested Under<BR>
17 C.F.R. &#167;&#167; 200.80(b)(4) and 240.24b-2</B>

</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><U>EXHIBIT A</U><BR>
<U>Payment Schedule</U>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="76%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left">Payment Date</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Amount of Payment</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Remaining Balance</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Balance Due, March&nbsp;18, 2009</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">10,500,000.00</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">April&nbsp;13, 2009</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">1,000,000.00</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">9,500,000.00</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">May&nbsp;13, 2009</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">1,500,000.00</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">8,000,000.00</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">June&nbsp;13, 2009</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">2,000,000.00</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">6,000,000.00</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">July&nbsp;13, 2009</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">1,500,000.00</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">4,500,000.00</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">August&nbsp;13, 2009</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">1,500,000.00</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">3,000,000.00</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">September&nbsp;13, 2009</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">1,500,000.00</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">1,500,000.00</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">June&nbsp;30, 2010</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">1,500,000.00</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">0.00</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="left">
<DIV style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96"></TD>
</TR>

<TR valign="top">
    <TD nowrap align="left">*</TD>
    <TD>&nbsp;</TD>
    <TD>CONFIDENTIAL TREATMENT REQUESTED &#151; This language has been omitted and filed separately with the Securities and Exchange Commission.</TD>
</TR>

</TABLE>




<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
KXEX10
KXNAME AKORN INC
